ORAMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ORAMED PHARMACEUTICALS INC. (ORMP) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 34.00 thousand shares as of 2024-06-20, per its 10-K filed 2025-03-27.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-03-27
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.48M shares, a 17.28% increase from fiscal 2022.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.26M shares.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 10.00K shares, a 98.54% decline from fiscal 2020.
- ORAMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 687.02K shares, a 62.36% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-06-20 | 34.00K shares 10-K · filed 2025-03-27 | |||||
| 2024-04-17 | 29.80K shares 10-K · filed 2025-03-27 | |||||
| 2024-01-30 | 3.75K shares 10-Q · filed 2024-05-09 | |||||
| 2024-01-04 | 187.61K shares 10-K · filed 2025-03-27 | 37.61K shares 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | 1.48M shares 10-K · filed 2024-03-06 | |||||
| 2023-05-01 | 20.00K shares 10-K · filed 2024-03-06 | |||||
| 2022-12-31 | 1.26M shares 10-K · filed 2024-03-06 | |||||
| 2022-07-28 | 34.00K shares 10-K · filed 2024-03-06 | 34.00K shares 10-K · filed 2023-03-06 | ||||
| 2022-05-02 | 7.50K shares 10-K · filed 2024-03-06 | 7.50K shares 10-K · filed 2023-03-06 | ||||
| 2022-01-03 | 150.00K shares 10-K · filed 2024-03-06 | 30.00K shares 10-K · filed 2023-03-06 | ||||
| 2021-08-31 | 10.00K shares 10-K · filed 2023-03-06 | |||||
| 2021-08-04 | 100.00K shares 10-K · filed 2023-03-06 | |||||
| 2021-02-17 | 15.00K shares 10-K · filed 2023-03-06 | |||||
| 2020-08-31 | 687.02K shares 10-K · filed 2021-11-24 | 943.65K shares 10-K · filed 2020-11-24 | ||||
| 2020-01-08 | 100.00K shares 10-K · filed 2021-11-24 | |||||
| 2019-08-31 | 423.15K shares 10-K · filed 2020-11-24 | |||||
| 2018-08-31 | 739.65K shares 10-K · filed 2018-11-28 | |||||
| 2017-08-31 | 808.78K shares 10-K · filed 2017-11-29 | |||||
| 2015-11-19 | 22.00K shares 10-Q · filed 2016-07-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |